Default company panoramic image

QuantumCor, Inc.

Transcatheter Mitral Valve repair via minimally invasive procedure that leaves no device behind. Animal studies completed successfully.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Seattle, WA, USA
  • Currency USD
  • Founded May 2005
  • Employees 6
  • Website

Company Summary

QuantumCor has developed a technology to allow physicians to repair a dysfunctional Mitral heart valve and treat functional Mitral Regurgitation (FMR) and congestive heart failure (CHF). This is done in a minimally invasive cardiac cath lab procedure, avoiding the need for open heart surgery. The technology restores valve function without leaving hardware in the heart and won’t conflict with other devices. It also preserves all future options.


  • Default avatar
    Vernon Dahl

    Extensive cardiovascular device experience (CPI/Guidant, Medtronic, Cordis, CardioMetrix, QuantumCor)
    CardioMetrix, VascuSense, InfoMedics, HMC

  • Default avatar
    Wayne Rebich

    CFO, VP Finance: private and public companies, Public accounting (KPMG), domestic and international assignments

  • Default avatar
    Duane Dickens

    CTO, VP, Director: engineering, product development, pilot manufacturing. Extensive cardiovascular and ablation catheter device experience (ACS/Guidant, Medtronic, Cardima, Volcano)

  • Default avatar
    Tom Witzel
    Director, Pre-Clinical Studies

    Research Scientist, Director Pre-Clinical, Director Animal Lab, Manager Physician Training
    Extensive animal lab and heart valve experience (Edwards Lifesciences, HeartPort, 3F Therapeutics, UC San Diego)

  • Default avatar
    Lori Glastetter
    Regulatory Affairs Officer

    VP, Quality and Regulatory Affairs. completed 130+ (IDE, PMA, 510K, CE) submissions in 55 countries.
    Extensive medical device experience (Edwards, Heartstream, Hewlett Packard, Northstar Neuroscience)


  • Default avatar
    See Medical Advisory Board listing in Executive Summary
    Default avatar
    CFO Wayne Rebich

Previous Investors

  • Default avatar
    As noted in collateral, Series A at $ 3.5M.